The combination therapy of sorafenib and triptolide on hepatocellular carcinoma affords greater efficacy than single-agent treatments in decreasing cell viability, inducing caspase-3, caspase-7 activity, and inhibiting NF-κB function [17]. This evidence concerns the gene CASP7 and hepatocellular carcinoma.